Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
SLE(Systemic Lupus Erythematosus) is an autoimmune disese that primarily occurs in women(9:1
compared to men). The disease is activated by genetic and environmental factors, yet the
female gender is the strongest risk factor. The sex hormone estrogen has been proven in the
past to be an enhancer of the immune response. Estrogen serves as a ligand for two specific
receptor proteins. Lab studies that we have already done have shown estrogen significantly
increases these two ligands in the T cells from SLE females, but not in T cells from normal
women. These estrogen-dependent increases are blocked by the estrogen receptor antagonist ICI
182,780. The objective of this research is to investigate if ICI 182,780 alters disease
progression and/or activity in females with SLE and may provide a new treatment for women
with SLE. This is based on previous work we have done.
Phase:
Phase 2
Details
Lead Sponsor:
The Center for Rheumatic Disease, Allergy, & Immunology